ClinicalTrials.gg

Program

tralesinidase alfa

Also written as “AX 250” and “Tralesinidase alfa (TA)”.

Its studies are mostly in Mucopolysaccharidosis III, led by 2 companies.

Furthest: phase 4, since Aug 5, 20224 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Allievex31 open or runningphase 4since Aug 5, 2022Feb 27, 2016Oct 2027phase 4 · NCT05492799
Spruce Biosciences11 open or runningphase 3since Apr 28, 2026Apr 28, 2026Aug 2033phase 3 · NCT07579910

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2016First study: phase 2 study in Mucopolysaccharidosis IIINew to AllievexAllievex · NCT02754076 · 23 enrolled · United States, Colombia, Germany and more
  2. Mar 30, 2018Phase 2 study in Mucopolysaccharidosis IIIAllievex · NCT03784287 · 20 enrolled · United States, Colombia, Germany and more
  3. Aug 5, 2022Phase 4 study in Mucopolysaccharidosis IIIAllievex · NCT05492799 · 15 planned · United States, Colombia, Germany and more
  4. Apr 28, 2026Spruce Biosciences’ first study: phase 3 study in Mucopolysaccharidosis IIINew to Spruce BiosciencesSpruce Biosciences · NCT07579910 · 14 planned

Ahead

  1. Oct 2027Primary completion: phase 4 study in Mucopolysaccharidosis IIIAllievex · NCT05492799
  2. Aug 2033Primary completion: phase 3 study in Mucopolysaccharidosis IIISpruce Biosciences · NCT07579910

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07579910Mucopolysaccharidosis III3Not yet recruitingSpruce BiosciencesAug 203314
NCT05492799Mucopolysaccharidosis III · United States, Colombia, Germany and more4By invitationAllievexOct 202715
NCT03784287Mucopolysaccharidosis III · United States, Colombia, Germany and more2UNKNOWNAllievexJan 202520
NCT02754076Mucopolysaccharidosis III · United States, Colombia, Germany and more2CompletedAllievexJun 24, 202023

How it is read

Names in the registry

  • “AX 250”, 3 entries
  • “Tralesinidase alfa (TA)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.